Visit COVID-19 resources

[Skip to Content]

Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study) – (Eye Journal AOP)

5 March 2015

This news item is available to RCOphth members only, please log in below to access.

Members Login